Get the Stockscreener App
12.70
2.58%
-0.275
Lenz Therapeutics Inc stock is traded at $12.70, with a volume of 158.21K.
It is down -2.58% in the last 24 hours and down -23.89% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$12.97
Open:
$13.12
24h Volume:
158.21K
Relative Volume:
0.15
Market Cap:
$395.82M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-2.2681
EPS:
-5.5973
Net Cash Flow:
$-73.92M
1W Performance:
-11.15%
1M Performance:
-23.89%
6M Performance:
-67.90%
1Y Performance:
-50.02%
1-Day Range:
$12.53
$13.19
1-Week Range:
$12.53
$14.58
52-Week Range:
$12.53
$50.40
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
12.65 | 405.83M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.97 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
799.96 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
846.57 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.38 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.03 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-25 | Resumed | Piper Sandler | Overweight |
| Mar-18-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Fund Flows: What is the cash position of LENZ Therapeutics IncEarnings Recap Report & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Is LENZ Therapeutics Inc. stock a value trapBreakout Watch & Advanced Technical Signal Analysis - mfd.ru
Is LENZ Therapeutics Inc. benefiting from interest rate changesWeekly Trading Summary & Low Risk High Win Rate Picks - mfd.ru
Guidance Update: Can LENZ Therapeutics Inc be the next market leaderEarnings Overview Summary & Low Risk Entry Point Tips - baoquankhu1.vn
No Need For Reading Glasses? Vizz Eye Drop That Improves Near Vision Has FDA Nod - MSN
Investment Recap: Why is LENZ Therapeutics Inc stock going upQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Analysts Offer Insights on Healthcare Companies: Orchestra BioMed Holdings (OBIO), LENZ Therapeutics (LENZ) and Amgen (AMGN) - The Globe and Mail
Aug Outlook: What are LENZ Therapeutics Incs recent SEC filings showingTrade Risk Summary & Technical Pattern Recognition Alerts - baoquankhu1.vn
Lenz Therapeutics price target lowered to $35 from $52 at BofA - TipRanks
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp By Investing.com - Investing.com South Africa
LENZ Therapeutics stock price target lowered to $35 at BofA on slower ramp - Investing.com
Why Is LENZ Therapeutics Stock Trading Lower Today?LENZ Therapeutics (NASDAQ:LENZ) - Benzinga
What is the cash position of LENZ Therapeutics Inc.July 2025 Closing Moves & Fast Exit Strategy with Risk Control - mfd.ru
Is LENZ Therapeutics Inc. stock a buy or sell2025 Biggest Moves & Precise Buy Zone Tips - mfd.ru
Bull Run: Will LENZ Therapeutics Inc outperform its industry peersJuly 2025 Retail & High Win Rate Trade Tips - baoquankhu1.vn
LENZ Therapeutics and Sarah Jessica Parker Launch ‘Make it VIZZable’ Campaign - VisionMonday.com
In first celebrity partnership, Lenz Therapeutics taps Sarah Jessica Parker for vision campaign - Medical Marketing and Media
Insider Trends: Is Okeanis Eco Tankers Corp a defensive stockEarnings Growth Report & Daily Oversold Stock Bounce Ideas - baoquankhu1.vn
Sovran Advisors LLC Has $4.98 Million Stock Holdings in LENZ Therapeutics, Inc. $LENZ - MarketBeat
Aug PostEarnings: Why is LENZ Therapeutics Inc stock going up2025 Support & Resistance & Free Weekly Watchlist of Top Performers - baoquankhu1.vn
Nasdaq Moves: Why is LENZ Therapeutics Inc stock going upRate Hike & Daily Market Momentum Tracking - baoquankhu1.vn
Trading Action: Is LENZ Therapeutics Inc stock a buy or sellPortfolio Value Summary & Real-Time Volume Spike Alerts - baoquankhu1.vn
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Unveiling a 155% Potential Upside in Biotechnology - DirectorsTalk Interviews
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ Therapeutics, Inc.LENZ - PR Newswire
Aug Spikes: What analysts say about LENZ Therapeutics Inc stockPortfolio Return Report & Risk Controlled Daily Plans - baoquankhu1.vn
We're Not Worried About LENZ Therapeutics' (NASDAQ:LENZ) Cash Burn - 富途资讯
Aug Shorts: Why is LENZ Therapeutics Inc stock going upProduct Launch & Weekly Stock Breakout Alerts - baoquankhu1.vn
LENZ Therapeutics and Sarah Jessica Parker announce the launch of Make it VIZZable, the VIZZ consumer campaign - marketscreener.com
LENZ Therapeutics (NASDAQ:LENZ) Trading Up 9.5%Should You Buy? - MarketBeat
Lenz Therapeutics, Sarah Jessica Parker launch ‘Make it VIZZable’ - TipRanks
LENZ Therapeutics Launches VIZZ Eye Drops for Near Vision Restoration Featuring Sarah Jessica Parker in "Make it VIZZable" Campaign - Quiver Quantitative
Lenz Therapeutics launch of "Make It Vizzable" with Sarah Jessica Parker as a brand ambassador - marketscreener.com
LENZ Therapeutics and Sarah Jessica Parker announce the launch of 'Make it VIZZable”, the VIZZ consumer campaign - The Manila Times
LENZ Therapeutics and Sarah Jessica Parker announce the launch of "Make it VIZZable", the VIZZ consumer campaign - PR Newswire
Sarah Jessica Parker Reveals the Health Issue That Almost Got in the Way of Her Favorite Pastime (Exclusive) - People.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of LENZ ... - Bluefield Daily Telegraph
Market Review: Will LENZ Therapeutics Inc stock continue upward momentumMarket Trend Review & Weekly Setup with ROI Potential - Bộ Nội Vụ
Shorts Report: How LENZ Therapeutics Inc stock reacts to global recession fearsTake Profit & Fast Exit Strategy with Risk Control - moha.gov.vn
A Look At LENZ Therapeutics (LENZ) Valuation After VIZZ Launch Momentum And New Lunatus Agreement - Yahoo Finance
Published on: 2026-01-12 22:19:01 - Улправда
Aug Momentum: Will LENZ Therapeutics Inc outperform its industry peers2025 Key Lessons & Real-Time Stock Price Movement Reports - baoquankhu1.vn
LENZ Therapeutics (LENZ) Is Down 7.1% After VIZZ Middle East Deal And Early Launch DataHas The Bull Case Changed? - Yahoo Finance
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
How sustainable is LENZ Therapeutics Inc. stock dividend payoutJuly 2025 Opening Moves & Long Hold Capital Preservation Tips - Улправда
Will LENZ Therapeutics Inc. stock see insider buyingJuly 2025 Short Interest & Accurate Intraday Trading Signals - Улправда
FOMO Trade: Why LENZ Therapeutics Inc. stock is recommended by analysts2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Exploring a Potential 245% Upside in the Biotechnology Sector - DirectorsTalk Interviews
LENZ Therapeutics Reports Preliminary Q4 2025 Results, Highlights VIZZ Launch - VisionMonday.com
Can LENZ Therapeutics Inc. stock reach $100 price targetJuly 2025 Patterns & Real-Time Buy Signal Alerts - ulpravda.ru
LENZ Therapeutics (NASDAQ:LENZ) Sets New 52-Week LowHere's Why - MarketBeat
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Olsson Shawn | Chief Commercial Officer |
Nov 17 '25 |
Sale |
26.10 |
10,000 |
261,022 |
4,733 |
0.71%
1.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):